MARLBOROUGH, Mass., Feb. 27, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) (the "Company") today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has completed a public offering of €750,000,000 aggregate principal amount of 3.375% notes due 2029 and €1,250,000,000 aggregate principal amount of 3.500% notes due 2032 (collectively, the "Notes"). The Notes are fully and unconditionally guaranteed by the Company. Application has been made for the Notes t ...

Have you been paying attention to shares of Boston Scientific (BSX) ? Shares have been on the move with the stock up 8.7% over the past month. The stock hit a new 52-week high of $67.32 in the previous session. Boston Scientific has gained 15.3% since the start of the year compared to the 7.8% move for the Zacks Medical sector and the 6.5% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our ea ...

The Boston Scientific logo is being displayed on a smartphone with a broken screen in Athens, ... [+] Greece, on February 2, 2024. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)NurPhoto via Getty ImagesBoston Scientific BSX (NYSE: BSX) reported its Q4 results last month, with revenues and earnings comfortably beating the street estimates. The company reported revenue of $3.7 billion and adjusted earnings of $0.55 per share, compared to the consensus estimates of $3.6 billion and $0.51, respectively. ...

MARLBOROUGH, Mass., Feb. 22, 2024 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of €750,000,000 aggregate principal amount of 3.375% notes due 2029 and €1,250,000,000 aggregate principal amount of 3.500% notes due 2032 (collectively, the "Notes"). The Notes will be fully and unconditionally guaranteed by the Company. The offering is being made pursuant to a ...

Boston Scientific, Inc. (BSX) appears in good shape, with its shares rallying 4.6% since the fourth-quarter earnings release. The company is gaining from strong worldwide demand for its GI and pulmonary treatment options. The traction in Europe for its next-generation WATCHMAN FLX and a contribution from accretive acquisitions are important growth drivers.The Zacks Rank #2 (Buy) stock has moved up 4.6% since the last earnings release compared with the industry’s rise of 1%. The Medical sector has increased ...

Boston Scientific (BSX) recently announced the completion of the first commercial cases in the United States with its FDA-approved Farapulse Pulsed Field Ablation (PFA) system.In January 2024, the company received the FDA clearance for the Farapulse PFA System. This made Boston Scientific the second company to have received an FDA nod for PFA for treating AFib.With the approval, Farapulse can be used to treat drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation in the isolation of pulmonar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-11083 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-2695240 (State or other jurisdiction of incorporation or organization) (I.R.S. ...

Boston Scientific Corporation (BSX) is gaining from strength across target markets. Strong worldwide demand for its GI and pulmonary treatment options, traction in Europe for its next-generation WATCHMAN FLX and contribution from accretive acquisitions are important drivers. However, unfavorable currency movements and stiff competition are a concern.In the past year, this Zacks Rank #2 (Buy) stock has gained 37.1% compared with a 5.5% fall of the industry and a 23.6% rise of the S&P 500.The renowned manufac ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks R ...

Boston Scientific, Inc. (BSX) recently gained the FDA’s approval for the FARAPULSE Pulsed Field Ablation (“PFA”) system, which is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation. The system represents a unique new alternative to standard-of-care thermal ablation treatment.Addressing the vast population living with paroxysmal atrial fibrillation (AF), the approval offers an incredible opportunity t ...